Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer to acquire Serenex
As per the agreement, Pfizer will acquire the rights to SNX-5422, an oral Hsp90 inhibitor currently in Phase I trials for the potential treatment of solid tumors and
As per the agreement, Pfizer will acquire the rights to SNX-5422, an oral Hsp90 inhibitor currently in Phase I trials for the potential treatment of solid tumors and
Under the terms of the collaboration, Raven will provide Emory with access to its prostate cancer stem cells. Raven will also provide Emory with a library of antibodies
Prior to joining Aldagen, Mr Carberry spent 27 years with Johnson & Johnson in a variety of financial leadership roles, including most recently as CFO of Johnson &
The terms of the agreement include national distribution of GenomicsRX DNA Personalized Genetics Analysis Kits into a network of more than 1000 spas and medspas across the country.
The study is intended to assess the safety and efficacy of SML’s experimental drug product, brostallicin. The trial will also be supported by the Sarcoma Foundation of America
In the collaboration, Pepscan will use its proprietary Clips technology to identify functional mimics of the essential parts of intractable targets. These mimics will be used by Genmab
This approval marks the first time Smith & Nephew’s technology will be available in the world’s second largest orthopaedic market. The Genesis II knee system will be the
The pivotal trial will be a multi-center, prospective, non-randomized study of 140 patients and will include up to 40 centers. The DuraHeart LVAS is a third generation circulatory
In this ruling, the Court found that the patent at issue was invalid, because it was obvious. Yasmin (drospirenone and ethinyl estradiol) provides an oral contraceptive regimen consisting
In important tests against a difficult-to-treat strain of human colon cancer cells (HCT116), scientists evaluated the performance of concentrated amounts of company’s newest anticancer compounds. Researchers observed a